What is the Probability of a Newcomer Getting FDA Clearance?

Medical Patents Broker Inc.
By Kenneth Pearce, President

Every year, brilliant doctors, engineers, and small LLCs file medical patents with the dream of taking their invention to the mass market and achieving global scale. What are the actual statistical probabilities of a newcomer successfully navigating the regulatory maze and getting that coveted “Go Sale”?

The Probability Breakdown: By The Numbers

• The 510(k) Track (Moderate Risk): ~80% to 85% Success Rate. If your medical device is a Class II and you can prove it is "substantially equivalent" to something already on the market (a predicate device), the odds are structurally in your favor. While the clearance rate is high, the FDA rejects or requests additional information on roughly 75% of first-time submissions from newcomers due to formatting and data errors. It often takes multiple expensive rounds to get it right. To get the “Go” to scale, significant marketing and positioning are needed to convince providers and CMS that the invention is a cost-efficient replacement in an already crowded market.
• The De Novo / Class III Track (High Risk) Success Rate. If the invention is a breakthrough technology, or a Class III life-sustaining device, the road has plenty of potholes. For pharmaceuticals and complex biologics, the historical probability of successfully moving from Phase I trials all the way to market is a brutal 9% to 10%.

Massive Capital Required to Move the Medical Invention

For the general public welfare, the FDA’s bureaucracy controls the rules and regulations of the game. Don’t play by the FDA requirements, and the game is dead. Play by the rules, and it’s possible to hit a homerun. However, especially for newcomers, the commercial dream can disappear because of three distinct hurdles:

• The Clinical Trial Wall: A newcomer can often fund a prototype, but when the FDA demands human clinical trials with verifiable data, the cash burn rate skyrockets into the millions.
• The “Deficiency” Trap: The FDA rarely approves a submission on the first pass. They issue “Additional Information” (AI) requests. A lack of capital to fund the drive and navigate these regulatory detours can crush the most devoted inventor.
• The Protocol Pitfall: Being new to the arena, innovators sometimes lack the regulatory hindsight to spot a flawed clinical protocol. Testing that wasn’t formulated in strict accordance with standard FDA guidelines is a nightmare to fix, if it’s fixable at all.

The President’s Viewpoint

Unless there is an unlimited supply of capital, the odds of a newcomer pulling a medical invention over the finish line and directly to market are bets that the house sets as long shots. To keep the invention moving toward the patient, it’s usually best to look for a strategic exit via cash or long-tail payments.

To meet the specific needs of our clients, Medical Patents Broker Inc. specializes in orchestrating straight sales, straight licenses, and hybrid transfers. To date, I have never watched a business overview fall into place exactly as originally planned. Detours are just part of the race.